You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

1552 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Document
Document
Document
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma
Drug
Other Name(s): Cabometyx®
Dec 1969
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib - For the treatment of advanced renal cell carcinoma (RCC), based on criteria
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib - For the treatment of unresectable, advanced hepatocellular carcinoma (HCC), based on criteria
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib - For the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible

Pages